Enzyme Engineering

& Industrial Fermentation

Enzymes are widely used as biocatalysts in the production or processing of a wide range of products including food, beverages, animal feeds, detergents, pharmaceuticals and textile products. Naturally occurring enzymes are often unstable or perform sub-optimally when moved from the biological to the industrial sphere.

Therefore, since the advent of protein engineering there have been efforts to improve these enzyme properties, and even to devise enzymes with novel specificities capable of producing types or quantities of metabolites not normally achievable in natural products. Such improvements or changes can often be challenging: enzyme activity depends on specific and highly complex structures, sometimes formed from multiple protein components, and requiring associated factors or metal ions to operate. Frequently, enhancing one desirable property comes at the cost of impairing another.

Mewburn Ellis has a long history of working with our clients in this fast-moving and competitive field. For example, we’ve been involved in protecting the ground-breaking innovations on the serine protease subtilisin (used for example in detergents and in food processing) since 1980s, and in multiple other enzymes in different fields such as brewing, biofuels and biopolymers. The Mewburn team has regularly and successfully defended patents covering our clients’ enzyme technologies at the EPO and assisted them in enforcing those patents before national courts. Engineered enzymes are typically produced in host species such as bacteria, yeasts and filamentous fungi and we also have many years’ experience in dealing with the fermentation technologies used for growing these microorganisms, and recovering the enzymes from them, whether at laboratory or industrial scale.

As more and more powerful computation tools are developed for determining and modelling protein structures, so protein engineers are increasingly able to analyse the structure-function characteristics for rationale design of novel enzymes, which can then be tested in large scale functional screening processes. Once again, our specialised team here is able to assist at our clients with obtaining protection for their intellectual property in the latest bioinformatics innovations in the enzyme space.

Open pages of Green IP Report

Green IP Report

Patents are both a driver and a barometer of innovation

Our report examines the role of patents in making innovative ‘green’ technologies into a reality as well as how the patent landscape can be used to identify opportunities for partnering, collaboration and investment.

We share our enthusiasm and admiration for commercially-focused innovation across a diverse range of technologies, from repurposing carbon dioxide to make protein-rich foods, to the multi-faceted approach to a circular plastics economy. We also discuss the tantalising prospect of AI-mediated renewable energy supply, and the harnessing of battery tech from the EV boom to drive energy efficiency in consumer devices. This report reflects our passion for technology solutions that tackle our shared global challenge.

Download the Report

Read our Blogs

“AI” in Bioprocessing – What’s Behind the Buzzword?

“AI” in Bioprocessing – What’s Behind the Buzzword?

by Anja Koller

At the 2026 Global Bioprocessing & Biotechnology Summit in Berlin, “AI” was a hot topic – from media development and enzyme screening to manufacturing, clinical data analysis and supply chain ...

Daya Ventures: The startup factory closing the gender health gap

Daya Ventures: The startup factory closing the gender health gap

by Frances Salisbury

Forward speaks to Daya Venture's CCO, Victorine Lançon as she tells Mewburn Ellis why 16 startups are just the beginning of a mission to improve women's healthcare in the most hands-on way possible.

EPO decision T 0655/24: A Strict Stance on Post-Filing Evidence

EPO decision T 0655/24: A Strict Stance on Post-Filing Evidence

by Chris Denison

Recently issued EPO decision T 0655/24 will be of great interest to those following antibody patenting at the EPO. It deals with several recurring themes, particularly around inventive step and ...

CRISPR‑Cas9 in Europe: the Current Situation and What Comes Next

CRISPR‑Cas9 in Europe: the Current Situation and What Comes Next

by Alex Galbraith

The discovery of CRISPR/Cas9, a groundbreaking biotechnology platform enabling precise DNA modification, ignited one of the most complex patent battles in recent memory. Multiple groups filed patents ...

Fast Growing Techbio: Data, Computational Research, IP and How to Leverage Those for Commercial Success

Fast Growing Techbio: Data, Computational Research, IP and How to Leverage Those for Commercial Success

by Christopher Casley

On Wednesday 6 May we were delighted to co-host a panel discussion and networking event: “Fast growing techbio: data, computational research, IP and how to leverage those for commercial success” at ...

PROTACs reach the market: what the first regulatory approval means for drug discovery and the patent landscape

PROTACs reach the market: what the first regulatory approval means for drug discovery and the patent landscape

by Andrew Pitts

Just as the attention of the pharmaceutical industry appeared to have shifted over the past few years towards biologics with blockbuster potential, a new and exciting therapeutic modality has emerged ...

Learn More
ME Forward Masthead White 2